New York health data analytics firm Cota has raised $40m in series C, led by IQVIA, which gains a seat on the board, and participated in by EW Healthcare Partners among others. Cota aims to address the value of healthcare, speed up drug development, optimise patient outcomes and reduce costs for payers in the sector using its Cota Nodal Address (CNA) precision disease classification system. Although the initial focus is on oncology, this is expected to broaden to other specialities; Cota CEO Memorial Sloan said the latest round would be used to grow the team and add new capabilities.
New York health data analytics firm Cota has raised $40m in series C, led by IQVIA, which gains a seat on the board, and participated in by EW Healthcare Partners among others. Cota aims to address the value of healthcare, speed up drug development, optimise patient outcomes and reduce costs for payers in the sector using its Cota Nodal Address (CNA) precision disease classification system. Although the initial focus is on oncology, this is expected to broaden to other specialities; Cota CEO John Hervey said the latest round would be used to grow the team and add new capabilities.